MedPath

Effect of Fluid Management Guided by Pulse Pressure Variation Vs Central Venous Pressure on Lung Water Assessed by Lung Ultrasound During Liver Transplantation

Not Applicable
Completed
Conditions
Lung; Congestive
Liver Transplantation
Interventions
Other: fluid therapy
Registration Number
NCT03243526
Lead Sponsor
Kasr El Aini Hospital
Brief Summary

the aim in this study to assess the effect of fluid management in patient undergoing orthotopic liver transplantation either by using pulse pressure variation or by central venous pressure. we will assess the impact of fluid management by either methods on oxygenation and extra vascular lung water visualized by lung ultrasound.

Detailed Description

After induction of anesthesia lung ultrasound will be performed and arterial blood gases (ABG) will be taken.

All patients in both groups will receive maintenance fluid in the form of crystalloids (ringer acetate) 4 ml/kg/H. Then fluid boluses will be given according to each group:

Group c (cvp): will receive 250 ml albumin 5% boluses to maintain CVP around 5 cmH2o Group P (ppv): will receive 250 ml albumin 5% boluses to maintain PPV below 13% as detected from invasive blood pressure monitor.

For all patients in both groups: blood transfusion will be indicated with decreased HB% level below 7 mg/dl in arterial blood gases. Other blood product (FFP, platelets and cryoprecipitate) transfusion will be guided by lab results and clinical status of patient. Plasma will be transfused if INR \> 1.5 and platelets will be transfused if count \< 50, 000

Lung ultrasound will be performed to diagnose EVLW. A Philips C5 ultrasound system (frequency 5Hz; Philips Medical Systems, Suresnes, France) with an ordinary echo probe will be used. Chest ultrasound will be performed using the 12 regions method. Intercostals spaces on each side will be examined anteriorly (midclavicular line), laterally (anterior axillary line) and posteriorly (posterior axillary line) Four ultrasound aeration patterns a. Normal aeration (N): 0 score ; line sliding sign associated with respiratory movement or less than 3 B lines ; b. Moderate loss of lung aeration: score 1 ; a clear number of multiple visible B-lines with horizontal spacing between adjacent B lines ≤ 7 mm (B7 lines) c. Severe loss of lung aeration: score 2; multiple B lines fused together that were difficult to count with horizontal spacing between adjacent B lines ≤ 3 mm (B3 lines); and d. Pulmonary consolidation: score 3; hyperechoic lung tissue, accompanied by dynamic air bronchogram.

The final LUS of the patient was the sum of each regional ultrasound score (ranging from 0 to 36).

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
40
Inclusion Criteria
  1. ASA physical status II- IV
  2. Child C (end stage liver disease) ESLD patient.
  3. Age (18- 70) years
  4. Patients undergoing orthotopic liver transplantation.
Exclusion Criteria
  1. Parents' refusal.
  2. Patients with chronic pulmonary disease ( Asthma, obstructive lung disease or restrictive lung diseases)
  3. Patient with impaired diastolic function more than grade I.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Central venous pressure groupfluid therapyfluid therapy to maintain CVP not 5 cmH2o
Pulse pressure variationfluid therapyfluid therapy will be guided by PPV to be less than 14%
Primary Outcome Measures
NameTimeMethod
lung ultrasound score5 minutes after surgical wound closure

lung score assessed by lung ultrasound to assess lung water. score range from 0 to 36

Secondary Outcome Measures
NameTimeMethod
P/F ratiobaseline 10 min after induction, 5 minutes after surgical wound closure and 1 hour after intensive care admission

ratio of Po2 to fraction of inspired oxygen.

lung ultrasound scorebaseline 10 minutes after induction. and 1 hour after Intensive care admission

lung score assessed by lung ultrasound to assess lung water. score range from 0 to 36

Trial Locations

Locations (1)

Kasr Alainy Hospital , Faculty of Medicine

🇪🇬

Cairo, Egypt

© Copyright 2025. All Rights Reserved by MedPath